In conclusion, pirtobrutinib emerges as a potentially transformative agent within the evolving therapeutic landscape of chronic CLL, particularly for patient cohorts with limited treatment options due to intolerance or resistance to conventional covalent BTK inhibitors (Figure 2). This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.